Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

PURPOSE: In the phase III CheckMate 238 study, adjuvant nivolumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB–C or stage IV melanoma, with benefit sustained at 4 years. We report updated 5-year effi...

Descripción completa

Detalles Bibliográficos
Autores principales: Larkin, James, Del Vecchio, Michele, Mandalá, Mario, Gogas, Helen, Arance Fernandez, Ana M., Dalle, Stéphane, Cowey, Charles Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Marquez-Rodas, Ivan, Butler, Marcus O., Di Giacomo, Anna Maria, Middleton, Mark R., Lutzky, Jose, de la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew G., Fecher, Leslie A., Millward, Michael, Nathan, Paul D., Khushalani, Nikhil I., Queirolo, Paola, Ritchings, Corey, Lobo, Maurice, Askelson, Margarita, Tang, Hao, Dolfi, Sonia, Ascierto, Paolo A., Weber, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472092/
https://www.ncbi.nlm.nih.gov/pubmed/37058595
http://dx.doi.org/10.1158/1078-0432.CCR-22-3145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472092/
https://www.ncbi.nlm.nih.gov/pubmed/37058595
http://dx.doi.org/10.1158/1078-0432.CCR-22-3145

Ejemplares similares